Trial Profile
A Study to Evaluate the Effects of Apremilast on QTc Interval in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2016
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Moxifloxacin
- Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 20 Jun 2016 New trial record
- 10 Jun 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics